The new algorithm is able to understand treatment patterns to deduce a patient's line of chemotherapy treatment, according to TriNetX, which announced the new offering at the SCOPE Summit last week in Orlando, FL.
“In clinical studies, researchers are probably looking at patients that are on their second or third or maybe even fourth line of treatment, as potential candidates for trials,” explained Jennifer Haas, vice president of marketing, TriNetX.
The offering is the latest component of TriNetX’s platform, which provides users with de-identified patient data integrated from EMRs, tumor registries, unstructured pathology reports, and molecular genomics data. This information is mapped onto the company’s network and is available for query, enabling users to analyze patient populations and perform "what-if" analyses, the company explained.
“As sponsors and CROs are going to look up and run their queries across our platform they now can leverage [the new] algorithm,” Haas told us at the summit.
Also of particular interest to oncology research, Haas explained the platform’s “rate of arrival” capabilities use predictive analytics to estimate the number of patients potentially available at a later date.
“That’s really helpful when designing protocols, because you then know that there will still be a cohort that you could potentially recruit,” she added.
TriNetX also this week announced that the Boston Children’s Hospital has joined its global health research network.